German Row Over Classification Of Telemonitoring Software Looks Set To Rumble On

Potential implications for telemonitoring software developers across the EU

When does an app qualify as a medical device and when does it not? A German court case appears to have wider-reaching implications for medtech than might first appear.

court house

Dermanostic, a German company based in Düsseldorf, is facing an ongoing legal challenge over the risk classification of its teledermatology software platform from competitor company, Online Doctor 24 but has so far been successful in defending its case.

Dermanostic has classified its product as a low-risk class I device in the context of the Medical Device Regulation....

Welcome to Medtech Insight

Create an account to read this article

More from Europe

Case Study: Pushing The EU’s IVD Regulation To Its Limits With Next Generation Sequencing

 

Partnership, positive communication and passion were all key in establishing a regulatory route for groundbreaking genetic testing technology for hereditary diseases. So said Fulgent Genetics’ executives interviewed by MTI about their technology’s development pathway.

EU Begins To Define Secondary Uses Of Health Data Under EHDS

 

The medtech industry, eagerly awaiting clear guidance on how healthcare data can be shared and help drive innovation, can have its say.

Should the EU Allow eIFU For Some Lay Devices?

 

Electronic instructions for use are becoming increasingly prevalent in the medtech world, but so far in the EU do not extend to non-professional users.

Rapid Flurry Of Late September EU Regulatory Developments

 

Recent key updates include new guidance on trend reporting, classification decisions, and opportunities for industry.

More from Geography

Case Study: Pushing The EU’s IVD Regulation To Its Limits With Next Generation Sequencing

 

Partnership, positive communication and passion were all key in establishing a regulatory route for groundbreaking genetic testing technology for hereditary diseases. So said Fulgent Genetics’ executives interviewed by MTI about their technology’s development pathway.

Blood Volume, Reimagined: Daxor’s BVA Could Slash Testing Time and Save Lives

 
• By 

The Daxor Blood Volume Analysis (BVA) is aimed at improving care for heart failure patients. It will allow blood volume to be measured from the patient’s bedside for the first time and is also significantly faster than earlier testing methods.

After Success Of Early Alert Pilot, FDA Builds Out Program To Include All Devices

 

The US FDA’s device center says the pilot program launched last year to streamline its recall process has been a success. It’s now starting to build off the program’s achievements, which means patients could be aware of potential safety issues from more types of devices.